| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3064668 | Journal of Neuroimmunology | 2010 | 7 Pages |
Abstract
We studied pDCs in MS patients and healthy subjects. The ability of pDCs to up-regulate CCR7 was significantly increased in untreated MS patients as compared to healthy subjects. IFN-beta treatment significantly inhibited TLR9 agonist-specific secretion of chemokines, which are ligands for CCR5-positive Th1 cells (CCL3, CCL4, and CCL5), and impaired TLR9 agonist-induced up-regulation of CCR7 and IFN-alpha in MS patients. This finding represents a new immunomodulatory effect of IFN-beta in patients with multiple sclerosis.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Latt Latt Aung, Patricia Fitzgerald-Bocarsly, Suhayl Dhib-Jalbut, Konstantin Balashov,